MedTrace Logo

Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir

NCT01577069 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2016-06-22

No results posted yet for this study

Summary

The purpose of the study is to

1- detect and quantify HCV-PI resistant mutants with ultra-deep pyrosequencing (UDPS) technology, 2 - detect SNPs in P-glyocoprotein and CYP3A genes, in HCV mono-infected patients under/after Telaprevir treatment.

Conditions

  • Chronic Hepatitis C

Sponsors & Collaborators

  • University Hospital, Bordeaux

    collaborator OTHER

  • Association HGE CHU Bordeaux Sud

    lead OTHER

Principal Investigators

  • Victor de lédinghen, MD, PhD · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01577069 on ClinicalTrials.gov